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Abstract. Ehm2 [also known as erythrocyte membrane 
protein band 4.1‑like protein 4B (EPB41L4B)] is a member 
of the NF2/ERM/4.1 superfamily. The overexpression of 
Ehm2 has been observed in metastatic cancer cells. Through 
alternative splicing, the Ehm2 gene produces two transcript 
variants that encode the two different isoforms, Ehm2/1 
and Ehm2/2. The biological functions of these different 
Ehm2 transcript variants remain unclear. The present study 
aimed to determine the expression of the Ehm2 variants in 
lung adenocarcinoma and their involvement in the disease 
progression of the patients. The expression of Ehm2 transcript 
variants in human lung adenocarcinoma tissues was analyzed 
using immunohistochemistry and western blot analysis. Ehm2 
variants were overexpressed or knocked down in A549 human 
lung adenocarcinoma cells. The consequent effects of the 
genetic modifications on the cellular functions of lung cancer 
cells were then examined using in vitro cell viability, invasion 
and migration assays. The expression of epithelial‑mesenchymal 
transition (EMT)‑related markers was evaluated by western 
blot analysis in the cell models. The association of Ehm2 
variant expression with patient survival was analyzed using 
Kaplan‑Meier survival analysis. The expression of Ehm2/1 
was significantly decreased in lung cancers compared with the 
paired normal lung tissues (P<0.05), while the Ehm2/2 protein 
levels were higher in the tumors than in the paired normal 
lung tissues, although this was not statistically significant. The 
overexpression of Ehm2/1 exerted inhibitory effects, while 
the knockdown of Ehm2/1 promoted the growth, invasion 
and migration of A549 cells in vitro. Ehm2/2 was expressed 
at low levels in the A549 cells and the enforced expression of 
Ehm2/2 significantly increased the invasiveness and migration 
of the A549 cells. Immunofluorescence staining revealed that 
Ehm2/1 was confined to the plasma membrane, while Ehm2/2 
was observed at both the plasma membrane and cytoplasm. The 
overexpression of Ehm2/1 resulted in the upregulation of the 
epithelial marker, E‑cadherin, and in the decreased expression 
of the mesenchymal markers, N‑cadherin and Snail1, while the 
knockdown of Ehm2/1 and the enforced expression of Ehm2/2 
had the opposite effects on the protein levels of EMT‑related 
markers. Kaplan‑Meier survival analysis revealed that higher 
Ehm2/1 transcript levels were associated with the longer 
survival of patients with lung adenocarcinoma, while the 
lower expression of Ehm2/2 exhibited a similar association 
with patient survival. Taken together, the two Ehm2 variants 
appear to be differentially expressed in lung adenocarcinoma. 
Ehm2/1 may function as a putative tumor suppressor in the 
disease progression of lung adenocarcinoma, while Ehm2/2 
may have an opposite function.
Introduction
To date, lung cancer remains as the leading type of cancer 
according to its incidence and mortality rate worldwide (1). 
It comprises two main histological subtypes, non‑small cell 
lung cancer (NSCLC) and small‑cell lung cancer (SCLC). 
Approximately 85% of lung cancer cases are NSCLC, which 
includes squamous cell carcinomas, adenocarcinomas and large 
cell carcinomas (2). The incidence of lung adenocarcinoma 
continues to increase in developed countries. It has become 
the most common subtype of lung cancer for both smokers 
and lifelong non‑smokers. However, relapse is commonly 
observed in 50 to 70% of patients within 1 year following 
surgical therapy, which is closely associated with the nature 
and quality of the surgery (3). Patients with NSCLC carrying 
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mutated epidermal growth factor receptor (EGFR) exhibit a 
good response to tyrosine kinase inhibitor (TKI) (4). However, 
resistance to TKIs acquired by cancer cells often limits the 
effects and corresponding benefits (5). Therefore, intensive 
research is required to shed light on the molecular and cellular 
machinery which are ‘hijacked’ or acquired by the lung cancer 
cells during tumor development and disease progression.
Ehm2, also known as erythrocyte membrane protein 
band 4.1‑like protein 4B (EPB41L4B), belongs to the Four.1 
protein, ezrin, radixin, moesin (FERM) superfamily. The 
overexpression of Ehm2 has been observed in metastatic cancer 
cells (6). FERM proteins contain a highly conserved FERM 
domain which mediates protein‑protein interactions through 
an interaction with the cytoplasmic tails of transmembrane 
proteins (7,8). FERM proteins are cytoskeletal‑associated 
proteins mediating interactions between transmembrane 
proteins and the cytoskeletal proteins. Upon an interaction 
with Crb3 through its FERM‑binding motif, Ehm2 can be 
recruited to the plasma membrane, leading to an activation 
of p114RhoGEF and the consequential control of the 
morphology and cohesion of cancer cells (9). Lulu2, a murine 
Ehm2 protein, has been shown to activate cortical myosin 
II to alter contractile force in epithelial cells (10). In human 
fibrosarcoma cells, Ehm2 has been reported to be involved in 
steroid‑regulated cytoskeletal reorganization (11).
As a metastasis‑associated protein, Ehm2 is frequently 
dysregulated in human solid cancers (6,12). The upregulation of 
Ehm2 has been observed in both tumor tissues and cell lines of 
prostate cancer (13). The overexpression of Ehm2 can promote 
prostate cancer progression and metastasis (13). The expression of 
Ehm2 is also elevated in breast cancers, which is associated with 
metastasis and a poor prognosis of patients with the disease (14). 
The knockdown of Ehm2 in MCF‑7 cells has been shown to not 
only increase apoptosis, but also to reduce invasiveness through 
a regulation of matrix metalloproteinase (MMP)9 (14).
Alternative splicing is a regulated process in gene expres‑
sion, which makes a single gene to encode different protein 
products. It naturally occurs in approximately 95% of 
multi‑exonic genes in eukaryotes (15,16), and is also involved 
in various disorders including cancers (17‑21). Through alterna‑
tive splicing, the Ehm2 gene produces two transcript variants, 
encoding two different isoforms, Ehm2/1 and Ehm2/2. The 
isoform 1 has 382 amino acids missing in its C‑terminal region 
in comparison with Ehm2/2 (11). Although the involvement of 
Ehm2 in disease progression is evident in both prostate and 
breast cancers, as discussed above, the exact role and function 
played by the two splice variants have yet to be elucidated.
In the present study, we examined the expression of the two 
Ehm2 transcript variants in lung adenocarcinoma tissues. The 
two variants exhibited distinct patterns of expression in lung 
cancers. In vitro cell function assays revealed that Ehm2/1 
exerted inhibitory effects, and that Ehm2/2 promoted both the 
migration and invasion of A549 cells. We also examined the 
association of the Ehm2 variants with epithelial‑mesenchymal 
transition (EMT) in lung cancer cells.
Materials and methods
Cells and cell culture. The A549 cell line was purchased from 
the American Type Culture Collection (ATCC, Manassas, 
VA, USA). The cells were cultured using Dulbecco's modified 
Eagle's medium (DMEM)‑F12 (Thermo Fisher Scientific, 
Waltham, MA, USA) which was routinely supplemented 
with 10% fetal bovine serum (Thermo Fisher Scientific) and 
penicillin/streptomycin (KGY0023; KeyGEN BioTECH, 
Nanjing, China) in an incubator at 37˚C with 5% CO2 and 
95% humidity.
Human lung cancer specimens. Fresh‑frozen NSCLC tissues 
(n=15) and matched adjacent normal lung tissues from the same 
patients were collected immediately following surgical resec‑
tion at Xuanwu Hospital of Capital Medical University (Beijing, 
China) after obtaining written informed consent. These tissues 
were stored at ‑80˚C until use. Clinicopathological informa‑
tion was collected and recorded in a database which includes 
sex, age, TNM stage, histological tumor type and lymph node 
metastasis. The clinicopathological characteristics of these 
tumor cases are presented in Table SI. All protocols were 
reviewed and approved by the Ethics Committee of Xuanwu 
Hospital.
Immunohistochemistry using tissue microarrays. Tumor 
tissue microarrays (TMA: HLug‑Ade060PG‑01) were 
purchased from Shanghai Outdo Biotechnology Co., Ltd. 
Each tissue microarray contained paraffin‑embedded 
sections from 30 lung adenocarcinoma tissues, as detailed in 
Table I, together with the paired normal tissues. Pathological 
diagnosis for these lung adenocarcinomas was available 
in the manufacturer's instructions. Immunohistochemical 
staining of tissue microarrays was performed as follows: 
After being dewaxed for 2 h at 60˚C and rehydrated by a 
gradient method, antigen retrieval was performed using 
a citrate buffer (10 mM citric acid, pH 6.0) followed by a 
blocking in a blocking buffer containing 5% bovine serum 
albumin. Primary antibodies against human Ehm2/1 
(1:200; AP338037; OriGene Technologies, Inc., Rockville, 
MD, USA) and human Ehm2/2 (1:50; ab135616; Abcam, 
Cambridge, UK) were used for probing (incubation for 
20 min at room temperature). A negative control was included 
without the addition of any primary antibodies. The sections 
were subsequently incubated with the relevant secondary 
antibody (ZSGB Biotechnology, Beijing, China) for 20 min 
at room temperature. Microarrays were visualized using 
diaminobenzidine (Cell Signal Technology, Inc., Danvers, 
MA, USA) with a counterstaining of nuclei using hematoxylin. 
All these processes were automatically carried out in a fully 
automated immunohistochemistry and in situ hybridization 
system (Leica BOND‑MAX; Leica Biosystems, Richmond, 
IL, USA).
Semi‑quantitative analysis of the intensity of Ehm2/1 and 
Ehm2/2 immunochemical staining in tissue microarrays. All 
immunochemical staining images in the tissue microarrays 
were acquired using a microscope which equipped with a 
digital camera (BX43; Olympus, Tokyo, Japan). The staining 
was assessed by two independent investigators who were 
blinded to the clinical information. The integrated optical 
density (IOD) of Ehm2/1 and Ehm2/2 staining in the tissue 
microarrays was determined using ImagePro® Plus software 
version 5.1 (Media Cybernetics, Inc., Rockville, MD, USA). 
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The average IOD/Ehm2 positively stained area (µm2) was 
calculated for the positively stained tissues.
Cell transfection. Expression plasmids of Ehm2/1 (RC223085) 
and Ehm2/2 (RC212424) tagged with FLAG were purchased 
from OriGene Technologies, Inc.. The shRNA targeting 
Ehm2/1 was purchased from Genechem Co. (Shanghai, China). 
Plasmid transfections were performed using jetPRIME® 
transfection reagent (Polyplus Transfection, Illkirch, France) 
according to the manufacturer's instructions. The cells were 
harvested for an analysis of gene expression approximately 
48 h following transfection. A549 wild‑type (A549 cells not 
transfected with any plasmid) and empty vector transfected 
(pCMV‑Entry) cells were used as controls.
Western blot analysis. The cells were lysed with a RIPA 
lysis buffer. Protein extracts were prepared from frozen 
tissues as follows. Tissues were homogenized using a protein 
isolation buffer [10 mM Tris‑HCl (pH 7.0), 160 mM NaCl, 
1% Triton X‑100, 1 mM EGTA, 1 mM EDTA, and Roche 
complete protease inhibitors]. The samples were incubated 
for 15 min on ice followed by a centrifugation at 16,000 x g 
for 30 min. The supernatants were stored at ‑80°C until 
use. A BCA protein assay kit (Thermo Fisher Scientific) 
was used to determine the protein concentration. A total of 
25 µg of protein samples were separated by sodiumdodecyl 
sulfate‑polyacrylamide gel electrophoresis followed by an 
electric blotting onto polyvinylidenedifluoride membranes 
(Merck Millipore, Billerica, MA, USA). Protein was probed 
with primary antibodies against Ehm2/1 (1:1,000; AP33087; 
OriGene Technologies, Inc.), Ehm2/2 (1:500; ab135616; 
Abcam), FLAG (1:1,000; F3165; Sigma, St. Louis, MO, 
USA), E‑cadherin (1:1,000; ab40772; Abcam), N‑cadherin 
(1:1,000; ab19348; Abcam), Snail1 (1:2,000; ab53519; Abcam), 
GAPDH (1:3,000; sc‑32233; Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA), at 4°C overnight. The horseradish 
peroxidase‑conjugated goat anti‑mouse antibody (1:5,000; 
115‑035‑003; Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA, USA) and goat anti‑rabbit antibody (1:5,000; 
111‑035‑03; Jackson ImmunoResearch Laboratories, Inc.) were 
incubated with the membranes for 1 h at room temperature. 
Protein bands were documented using a chemiluminescence 
(ECL) detection system (FusionFx; VilberLourmat, Collégien, 
France). Protein expression was determined by densitometric 
analysis using Image J software (version 1.62; National 
Institutes of Health, Bethesda, MD, USA). Quantitative 
densitometric values of all proteins were normalized to 
GAPDH.
In vitro cell viability assay. The cells were seeded into 96‑well 
plates at a density of 3x103 cells per well. Cell viability 
was then evaluated using a Cell Counting Kit‑8 (CCK8; 
Dojindo, Kumamoto, Japan). Absorbance was determined at 
a wavelength of 450 nm using a spectrophotometer (BioTek, 
Winooski, VT, USA).
Wound healing assay. The cells were plated into 12‑well 
plates at a density of 6x105 cells per well and allowed to 
Table I. Clinicopathological characteristics of the 30 tumor cases.
Parameters Category Cases, n=30 Percentage (%)
Tissue paired samples Tumor 30
 Normal 30
Lymph node status N0   4   13
 N>1 26   86
Pathological grades Ⅰ   5   17
 Ⅱ 19   63
 Ⅲ   6   20
TNM staging TNM Ⅰ   3   10
 TNM Ⅱ 14   47
 TNM Ⅲ 13   43
 TNM Ⅳ   0     0
Age, years ≤40   3   10
 41‑56   6   20
 ≥56 21   70
Mean ± SD 57.11±10.09
Sex Male 11   37
 Female 19   63
Pathological types Adenocarcinoma 30 100
 Squamous cell carcinoma   0     0
SD, standard deviation.
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form a monolayer. The cells were wounded with a fine gauge 
needle to create a wound. The migration of the cells was 
recorded using an inverted microscope (CKX41; Olympus 
Corp., Tokyo, Japan). Images were captured using a camera 
(EOS600D; Canon, Tokyo, Japan) at the indicated time point. 
The migration distances were determined and analyzed using 
Image J software (version 1.62).
In vitro invasion assay. Matrigel (BD Biosciences, San Jose, 
CA, USA) was used to pre‑coat Transwell cell culture inserts 
(8 µm pore size, 28617043; Costar, New York, NY, USA) and 
air dried. Following rehydration, 20,000 cells were seeded 
into each insert. Following 2 days of incubation, the invaded 
cells were fixed in 4% formalin, followed by staining with 
0.5% crystal violet (0528; Amresco Inc., Solon, OH, USA) for 
15 min at room temperature. The absorbance was measured at 
490 nm using a spectrophotometer (BioTek).
Gelatin zymography assay. The activities of MMPs were 
assayed as previously described (14). The cells were seeded 
into tissue culture flasks at a density of 1x106 cells. Once 
the cells reached 80% confluency, they were washed with 
phosphate‑buffered saline (PBS) and further cultured in 
serum‑free medium. After 6 h, conditioned medium was 
collected and concentrated through an Amicon Ultra‑0.5 
ml centrifugal filter (Merck Millipore, East Midlands, UK). 
Protein samples were prepared using a non‑reducing sample 
buffer. Protein samples were separated via 10% SDS‑PAGE 
containing 0.1% gelatin. Following electrophoresis, the gels 
were washed and incubated overnight at 37˚C. Following 
incubation, the gels were stained with Coomassie blue and 
subsequently scanned on digital scanner images (HP Scanjet 
G3110; HP Development Co., Beijing, China).
Immunofluorescence staining of cells. The cells were seeded 
on coverslips. Following fixation with 4% paraformaldehyde, 
the cells were washed 3 times with ice‑cold phosphate‑buffered 
saline (PBS), and then permeabilized for 30 min. The cells 
were then incubated with anti‑FLAG (1:100; F3165; Sigma) 
antibody at room temperature for 1 h followed by further 
1 h of incubation at room temperature with Alexa Fluor® 
488‑conjugated goat anti‑mouse secondary antibody (1:200; 
A11029; Thermo Fisher Scientific). The slides were mounted 
using ProLong® Gold Antifade Mountant with DAPI (P36931; 
Thermo Fisher Scientific). A Leica SP8 confocal microscope 
(Leica Microsystems, Wetzlar, Germany) was used to photo‑
graph the slides.
RNA preparation and reverse transcription‑polymerase chain 
reaction (RT‑PCR). RNA extraction and RT‑PCR were 
performed as previously described (22). Total RNA was isolated 
from frozen lung cancer tissues and lung adenocarcinoma 
A549 cells using TRIzol® reagent (15596018; Thermo Fisher 
Scientific). cDNA was generated from 1 µg RNA sample using 
an iScript™ cDNA Synthesis kit (1708891; Bio‑Rad 
Laboratories, Inc., Hercules, CA, USA). The reaction conditions 
for reverse transcription were as follows: 25˚C for 5 min, 42˚C 
for 30 min, and 85˚C for 5 min. PCR was carried out using a 
REDTaq™ ReadyMix PCR reaction mix (R2523; Sigma) 
according to the manufacturer's instructions. The reaction 
conditions for PCR were as follows: 94˚C for 5 min for initial 
denaturation, followed by 30 cycles of 94˚C for 10 sec, 56˚C for 
20 sec and 72˚C for 30 sec. The PCR primers were as follows: 
Ehm2/1 sense, 5'‑CACTTTGAGAGACTGAAGCA‑3' and 
antisense, 5'‑CAACTTCTACGACAGGAATATATGC‑3'; 
Ehm2/2 sense, 5'‑CCTGTTGCGGATCATGTGAAGTG‑3' 
and antisense, 5'‑TATCAGGAAACGGGTTCATTGTATC‑3'; 
and GAPDH sense, 5'‑GGGAAGGTGAAGGTCGGAGT‑3' 
and antisense, 5'‑TTGAGGTCAATGAAGGGGT‑3'. The 
products were visualized on a 1.2% agarose gel stained with 
GoldView (G8140; Solarbio, Beijing, China).
Quantitative polymerase chain reaction (qPCR). qPCR was 
performed utilizing the ABI 7500 Fast Real‑time PCR system 
(Applied Biosystems, Foster City, CA, USA) through the 
measurement of real‑time SYBR‑Green f luorescence 
(1708880; Bio‑Rad Laboratories, Inc.), and the results were 
obtained by means of the comparative Cq method (2‑ΔΔCq) 
using GAPDH as an internal control (23). This experiment was 
performed in triplicate. The following condition was used in 
the reaction: 94˚C for 5 min for initial denaturation, followed 
by 40 cycles of 94˚C for 10 sec, 56˚C for 20 sec and 72˚C for 
30 sec. The PCR primers were as follows: Ehm2/1 sense, 
5'‑TGAAGGTCGCATTGGAAAG‑3' and antisense, 5'‑CAT 
CATACTTTGCATCCCTCC‑3'; Ehm2/2 sense, 5'‑GTTGCG 
GATCATGTGAAGTG‑3' and antisense, 5'‑TGATTCCTC 
CTTTCCACCCT‑3'; GAPDH sense, 5'‑CTGAGTACGTCG 
GGAGTC‑3' and antisense, 5'‑GAGATGATGACCCTTTTG‑3'.
Lung cancer survival analysis. The overall survival (OS), 
progression‑free survival (PFS) and post‑progression survival 
(PPS) of the patients with lung cancer was carried out using the 
web tool Kaplan‑Meier Plotter (http://kmplot.com/analysis/). 
The Ehm2/1and Ehm2/2 probe sets were 220161_s_at and 
233098_s_at, respectively.
Comparision of sequences of Ehm2/1 and Ehm2/2 in 
Ensemble and UCSC. Ensemble (http://asia.ensembl.org) is a 
genome browser for vertebrate genomes that supports research 
in comparative genomics, evolution, sequence variation, and 
so on. We queried Ehm2 (EPB41L4B) in human and found 
two transcripts for protein coding. UCSC Genome Browser 
(http://genome.ucsc.edu) can also provide the information 
of the Ehm2 transcript variants through the nearest 
mirror‑genome‑asia.ucsc.edu (http://genome‑asia.ucsc.edu).
Statistical analysis. The SPSS software package version 19.0 
(SPSS, Inc., Chicago, IL, USA) was used for the statistical 
analyses. Statistical analysis was performed using ANOVA 
and a Bonferroni post hoc test for multiple group comparisons. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Differential expression of Ehm2/1 andEhm2/2 in human lung 
adenocarcinoma specimens. To analyze the protein levels 
of Ehm2 variants in lung cancer, the immunohistochemical 
staining of Ehm2/1 and Ehm2/2 was performed on tissue 
microarrays which comprised 30 human lung adenocarcinoma 
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tissues paired with non‑cancerous tissues. Two tissue sections 
were invalid due to mounting issues and were excluded from 
the analyses. All information regarding the microarray tumor 
specimens is presented in Table I. The staining for Ehm2/1 
was significantly decreased in the lung adenocarcinoma tissues 
compared with the paired normal tissues (P=0.0004, n=28; 
Fig. 1A and B), while the increased expression of Ehm2/2 
was observed in comparison to the paired normal tissues 
(P=0.0060, n=28; Fig. 1A and B). We also determined the 
protein expression of these two Ehm2 variants in lung cancer 
tissues by western blot analysis. The normal lung tissues 
predominantly expressed Ehm2/1 (Fig. 1C). Similarly, Ehm2/1 
expression was markedly decreased in lung cancer tissues in 
comparison with the controls (P<0.01, n=15; Fig. 1D). Ehm2/2 
was found to be upregulated in the lung adenocarcinoma 
tissues compared with the adjacent normal tissues, but this 
did not reach a level of significance (P=0.3, n=10; Fig. 1D). 
Our attempts to quantitatively analyze the mRNA expression 
levels of Ehm2/1 and Ehm2/2 in human samples using 
quantitative PCR were not successful owing largely to the 
fact that an insufficient quantity of mRNA isolated from these 
tissues was not adequate for the assay. Thus, it is clear from 
the above‑mentioned immunohistochemistry results that the 
expression of Ehm2/2 was significantly increased in the lung 
adenocarcinomas (P=0.006). Taken together, from the results 
of immunohistochemistry and western blot analysis, it is clear 
that the expression of the two Ehm2 transcript variants differs 
in human lung adenocarcinoma.
Ehm2/1 regulates the proliferation, migration and invasion 
of A549 cells in vitro. To examine the function of Ehm2/1 in 
lung adenocarcinoma, the human lung adenocarcinoma cell 
line, A549, was used to create an overexpression cell model. 
The endogenous expression of Ehm2 in the A549 cells is 
Figure 1. The two Ehm2 transcript variants were differentially expressed in human lung cancers. (A) Representative immunohistochemical staining of Ehm2/1 
and Ehm2/2 in lung adenocarcinoma tissue microarrays. The square boxes in the images on the left panels showing the ‘Normal’ and ‘Tumor’ tissues are 
higher magnification images (cale bar, 100 µm) of the images on the right of these panels (scale bar, 20 µm). (B) Semi‑quantitative integrated optical density 
of Ehm2/1‑and Ehm2/2‑positive staining was assayed in tissue microarrays. **P<0.01 and ***P<0.001. (C) Ehm2/1 and Ehm2/2 expression were determined in 
protein samples derived from human lung cancer tissues (T) together with paired adjacent normal lung tissues (N). (D) Semi‑quantitative analyses of Ehm2/1 
and Ehm2/2 expression in (C) were performed using ImageJ software. The quantification of protein levels relative to GAPDH is shown. ***P<0.001.
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shown in Fig. S1. Western blot analysis was performed to 
verify the expression of Ehm2/1 in the transfected cells 
(Fig. 2A). Compared with the A549 wild‑type (A549 cells 
not transfected with any plasmid) and empty vector‑trans‑
fected (pCMV‑Entry) control cells, the overexpression of 
Ehm2/1 exerted an inhibitory effect on cell proliferation 
in vitro (P<0.001, when compared with pCMV‑Entry 
control; Fig. 2B). Ehm2/1 overexpression markedly reduced 
the malignant phenotype of A549 cells, including invasive‑
ness and migration (P<0.05 and P<0.01, respectively, when 
compared with pCMV‑Entry; Fig. 2C and D). A knockdown 
model of Ehm2/1 in the A549 cells was also employed to 
verify the findings. A decreased expression of Ehm2/1 was 
observed in the cells in which Ehm2/1 was knocked down 
(shEhm2/1) compared with the A549 wild‑type and empty 
vector‑transfected cells (Scr) (Fig. 2E). The knockdown 
of Ehm2/1 expression resulted in a significant increase in 
cell growth in vitro (P<0.05, when compared with empty 
vector‑transfected cells; Fig. 2F), invasion (P<0.01, when 
compared with empty vector‑transfected cells; Fig. 2G) and 
Figure 2. Ehm2/1 inhibits the biological functions of A549 human lung adenocarcinoma cells. (A) The overexpression of Ehm2/1 in A549 cells (Ehm2/1) 
was validated by western blot analysis. (B) A549 cells transfected with control vector and Ehm2/1 plasmid were subjected to cell viability assay. Shown are 
representative data from 3 independent experiments. Error bars represent standard deviations. ***P<0.001 when compared with pCMV‑Entry control. (C) A549 
cells transfected with control vector and Ehm2/1 plasmid were subjected to Transwell insert invasion assay. Invaded cells were stained and measured. Shown 
were representative data from 3 independent experiments. Error bars represent standard deviations. *P<0.05. (D) A549 cells transfected with control vector and 
Ehm2/1 plasmid were wounded and the migration of cells was recorded. Shown are representative data from 3 independent experiments. Error bars represent 
standard deviations. **P<0.01 and ***P<0.001 when compared with pCMV‑Entry. (E) Knockdown of Ehm2/1 in A549 cells (shEhm2/1) was confirmed by 
western blot analysis. Scr represents the empty vector control. (F‑H) A549 cells transfected with control vector and Ehm2/1 shRNA were subjected to (F) cell 
viability, (G) invasion and (H) migration assays. Representative data are shown from 3 independent experiments. Error bars represent standard deviations. 
*P<0.05 and **P<0.01 when compared with empty vector‑transfected cells. pCMV‑Entry represents the empty vector control, and wt represents A549 wild‑type 
cells.
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cell migration of the A549 cells (P<0.05, when compared 
with empty vector‑transfected cells; Fig. 2H).
The invasive potential of the cancer cells is linked to their 
ability to degrade the extracellular matrix, which to a large 
degree is catalyzed by MMPs. Thus, in this study, we further 
determined the activities of MMPs from the cells with the 
differential expression of Ehm2 variants, using gelatin 
zymography assay. There was a marked increase in the 
activities of MMPs in the A549 cells in which Ehm2/1 was 
knocked down (Fig. S2). These findings indicate that Ehm2/1 
is a negative regulator of A549 cell viability, invasion and 
migration.
Ehm2/2 expression promotes A549 cell invasion and 
migration. An Ehm2/2 overexpression cell line model was 
also generated to examine the regulatory role of this molecule 
in lung cancer cells. The expression level of Ehm2/2 was found 
to be considerably elevated in the Ehm2/2‑overexpressing 
cells (Fig. 3A). The overexpression of Ehm2/2 was found to 
promote the proliferation of the A549 cells in comparison 
with the wild‑type cells and empty vector‑transfected 
control cells, although this difference was not statistically 
significant (Fig. 3B). In comparison to the control groups, the 
overexpression of Ehm2/2 markedly increased the invasion of 
the A549 cells (P<0.05, when compared with pCMV‑Entry 
control; Fig. 3C). The ectopic expression of Ehm2/2 also 
markedly promoted cell migration (P<0.01, when compared 
with pCMV‑Entry control; Fig. 3D). In addition, gelatin 
zymography assay also revealed an increase in the activities 
of MMPs in the Ehm2/2‑overexpressing cells (Fig. S2). Taken 
together, these data suggest that Ehm2/2 is a promoter of A549 
cell invasion and migration.
Subcellular distribution of Ehm2/1 and Ehm2/2 differs in A549 
cells. From the Ensemble and UCSC websites, we identified 
that Ehm2/1 variant lacks several exons and has a different 
3'‑terminal exon (data not shown). This results in Ehm2/2 
with a long C‑terminus and makes it longer than Ehm2/1. 
FERM proteins have been reported to have additional protein 
functions in the C‑terminal region, including an autoregulatory 
function that inhibits FERM domain activity (8,24). Although 
thus far no functional domain has been found based on protein 
sequence alignment in the C‑terminal region of Ehm2/2, 
at least to the best of our knowledge, we hypothesized that 
this C‑terminal region may be important for its function and 
subcellular distribution through interacting with its FERM 
domain or with other proteins. Combined with differential 
expression patterns and differential effects on A549 cell 
function, we hypothesized that Ehm2 variants have distinct 
subcellular distributions. To examine this possibility, we 
performed immunofluorescence staining of the A549 
cells following the ectopic overexpression of Ehm2/1 and 
Ehm2/2. As shown in Fig. 4, Ehm2/1 was mainly found in 
the cell membrane (Fig. 4A), while Ehm2/2 was more widely 
distributed from the cell membrane, the cytoplasm and was 
even found in the nuclei (Fig. 4B). These results suggest that 
Ehm2 variants have different distributions.
Ehm2/1 and Ehm2/2 influence EMT‑marker expression in an 
opposing manner. It is known that the process of EMT enables 
cell migration and invasion. In consideration that Ehm2 
variants regulate the invasion and migration of A549 cells, in 
this study, we detected the effects of Ehm2/1 and Ehm2/2 on 
EMT marker expression. The ectopic expression of Ehm2/1 
resulted in the decreased expression of N‑cadherin and Snail1, 
Figure 3. Overexpression of Ehm2/2 promotesthe biological functions of A549 human lung adenocarcinoma cells. (A) The expression of Ehm2/2 in A549 cells 
(Ehm2/2) was determined by western blot analysis. (B) A549 cells transfected with control vector and Ehm2/2 plasmid were subjected to cell viability assay. 
Shown are representative data from 3 independent experiments. Error bars represent standard deviations. (C) A549 cells transfected with control vector and 
Ehm2/2 plasmid were subjected to invasion assay. Invaded cells were stained and measured. Shown are representative data from 3 independent experiments. 
Error bars represent standard deviations. *P<0.05. (D) A549 cells transfected with control vector and Ehm2/2 plasmid were wounded and the migration of 
cells was recorded. Three independent experiments were performed. Shown are representative data. Error bars represent standard deviations. **P<0.01 and 
***P<0.001 when compared with pCMV‑Entry control.
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whereas the expression of E‑cadherin was elevated (Fig. 5A). 
In line with this result, the knockdown of Ehm2/1 resulted 
in the downregulation of E‑cadherin expression and 
in the upregulated expression of both N‑cadherin and 
Snail1 (Fig. 5B). However, the overexpression of Ehm2/2 
resulted in the increased expression of N‑cadherin and Snail1, 
and in the decreased expression of E‑cadherin (Fig. 5C). These 
results indicate that Ehm2/1 inhibits and Ehm2/2 promotes 
EMT in lung cancer cells.
Ehm2/1 transcripts are positively associated with and Ehm2/2 
transcripts are negatively associated with the longer survival 
of patients with lung cancer. In order to further elucidate 
the clinical implication of Ehm2 variants in lung cancer, we 
analyzed the association of Ehm2/1 (Affy ID 220161_s_at) 
and Ehm2/2 (Affy ID 233098_s_at) with patient survival using 
Kaplan‑Meier survival analysis (http://kmplot.com/analysis/). 
Lower expression levels of Ehm2/1 were associated with a 
shorter OS (P=6.3e−06; Fig. 6A) and PFS (P=0.027; Fig. 6B). 
A lower expression of Ehm2/1 was also associated with a 
poorer PPS (P=0.0065; Fig. 6C). In contrast to Ehm2/1, a 
higher Ehm2/2 expression was observed in patients who had a 
poorer OS (P=0.023; Fig. 6D) and PFS (P=0.58; Fig. 6E). The 
elevated Ehm2/1 expression was also associated with a poor 
PPS (P=0.032; Fig. 6F). Taken together, these results indicate 
that Ehm2/1 inhibits and Ehm2/2 promotes disease progres‑
sion and the relapse of lung cancer.
Discussion
In the current study, we demonstrated that two transcript 
variants of Ehm2 had distinct expression patterns in lung 
adenocarcinoma and had a different association with patient 
survival in lung cancer. We further demonstrated that the 
two transcript variants of Ehm2 had opposite effects on the 
functions of A549 cells and EMT in A549 cells. Our data 
Figure 4. Subcellular distribution of Ehm2 variants in A549 cells. Immunofluorescence staining for Ehm2/1 and Ehm2/2 (green) and nuclei (DAPI; blue) were 
performed using A549 cells overexpressing (A) Ehm2/1 and (B) Ehm2/2.
Figure 5. Protein expression levels of the epithelial‑mesenchymal transition‑related markers, E‑cadherin, N‑cadherin, and Snail1 were assessed by western blot 
analysis. (A) Ehm2/1‑overexpressing cells, (B) cells in which Ehm2/1 was knocked down, (C) Ehm2/2‑overexpressing cells.
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suggest that Ehm2/1 is a putative tumor suppressor during 
the disease progression and metastasis of lung cancer, while 
Ehm2/2 may have an opposite function.
The roles played by Ehm2 in cancer appear to be 
controversial. As a metastasis‑associated protein, Ehm2 has 
been reported to be highly expressed in prostate and breast 
cancers, which is associated with disease progression and 
metastasis (13,14). On the other hand, Ehm2 has been shown to 
exert an inhibitory effect on the migration of HeLa cells by the 
regulation of cell morphology and cohesion as a downstream 
molecule of CRB3A (25). In fact, Ehm2 in these studies should 
be considered as total Ehm2, as the anti‑Ehm2 antibody used 
in these studies recognizes an internal region of Ehm2, which 
is a sequence conserved in both Ehm2/1 and Ehm2/2. However, 
which transcript variants dominate in these processes has yet 
to be elucidated. In this study, we used different antibodies 
specific to Ehm2/1 and Ehm2/2 to evaluate the expression and 
functions of these transcript variants in lung adenocarcinoma. 
In the present study, a decreased expression of Ehm2/1 was 
found in lung cancers, while an upregulation of Ehm2/2 was 
observed in the tumors. Significant associations were found 
between the reduced transcript levels of Ehm2/1 and poorer 
OS, PFS and PPS, while higher transcript levels of Ehm2/2 
were associated with a poorer OS and PPS. Our results indicate 
that the two transcript variants have differential expression 
patterns and opposing functions in lung cancer development.
In line with their clinical implication, our in vitro 
experiments revealed that Ehm2/1 and Ehm2/2 have opposite 
effects on the functions of human lung adenocarcinoma A549 
cells. A significant reduction in cell growth, migration and 
invasion in vitro was observed in Ehm2/1‑overexpressing 
A549 cells. By contrast, Ehm2/1 knockdown led to a significant 
increase in the growth, migration and invasion of A549 
cells. The overexpression of Ehm2/2 markedly promoted the 
migration and invasion of A549 cells. Our data suggest that 
Ehm2/1 is a putative suppressor of disease progression in lung 
cancer, while Ehm2/2 may play an opposing role. In fact, it 
is well known that different transcript variants of a gene may 
Figure 6. Association between Ehm2 transcript variants expression and survival of patients with lung cancer was analyzed by Kaplan‑Meier analysis. Ehm2/1 
expression and (A) overall survival, (B) progression‑freesurvival, (C) and post‑progression survival. (D‑F) Association between Ehm2/2 expression and 
clinical outcome, as analyzed for (D) overall survival, (E) progression‑free survival and (F) post‑progression survival.
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have different or opposing biological functions. For example, 
human osteopontin (OPN), has the 3 transcript variants 
of OPN‑a (full‑length form), OPN‑b (lacking exon 5) and 
OPN‑c (lacking exon 4). Chae et al demonstrated that OPN‑a 
and OPN‑b were predominantly expressed in hepatocellular 
carcinoma tissues, while OPN‑c was expressed in normal liver 
tissues. The overexpression of OPN‑a and OPN‑b promoted 
the migration of Hep3B cells, while OPN‑c exerted minimal 
effects. However, OPN‑c inhibited the migrate of SK‑Hep1 
cells, while OPN‑a overexpression had no effect (26).
Ehm2 contains a conserved FERM domain that is 
involved in the interaction between cytoplasmic proteins 
and transmembrane proteins via its FERM domain (27). 
Laprise et al revealed that Yurt, the Drosophila orthologue 
of Ehm2, can bind to Crb through its FERM domain and be 
recruited to the apical membrane (28). EPB41L5, a protein 
sharing a high homology with Ehm2, has been shown to 
bind with intracellular domain of Crumbs through its FERM 
domain, which is involved in the regulation of cell polarity (29). 
A predominant expression of endogenous Ehm2/1 at the cell 
membrane has been observed in a breast cancer cell line 
(MCF‑7) in our previous study (22). In accordance with 
these results, the present study also revealed a predominant 
distribution of Ehm2/1 at the cell membrane in theA549 cells. 
By contrast, exogenous Ehm2/2 was widely distributed in the 
cells, including the cell membrane, cytoplasm and even the 
nucleus. As mentioned above, Ehm2/2 is longer than Ehm2/1 
and has a longer C‑terminal. Although structural analysis 
identified no specific domains in the C‑terminus of Ehm2/2, 
we hypothesized that the C‑terminus might be related to the 
different subcellular localization of the molecule, which is yet 
to be investigated. The present study clearly demonstrated 
that the two Ehm2 transcript variants have different 
expression patterns, different subcellular distributions and 
opposing biological functions. It is thus highly probable 
that different cellular distributions of Ehm2 variants may 
be one cause leading to varying biological functions. In 
our previous study, we reported that Ehm2/1 functions as a 
putative tumor suppressor in the disease progression of breast 
cancer (14). In our ongoing studies, we found that Ehm2/1 
may stabilize E‑cadherin by inhibiting its ubiquitination and 
degradation (unpublished data). It is therefore argued that 
different distributions of Ehm2 variants in different cellular 
compartments enable them to exert biological functions via 
different signaling pathway. This would be an exciting area to 
explore in the future. The current research findings also raised 
another question as to whether the two transcript variants 
interact with each other. Presently, there is no direct and solid 
evidence to suggest that the two variants do interact. However, 
in our humble opinion, and from these protein sequences, the 
two transcript variants of Ehm2 are unlikely to interact with 
each other. Indeed, to the best of our knowledge, there has 
been no report to date showing FERM proteins interacting 
with each other, a notion worthwhile to explore in the future.
EMT is a highly regulated process, which is associated 
with the enhanced migration and invasion of cancerous cells, 
thus contributing to the local invasion and metastasis of cancer 
cells. EMT is typically defined by the loss of the epithelial 
phenotype and the acquiring of mesenchymal characteristics, 
leading to reduced cell‑cell adhesion, increased motility and 
invasiveness and strengthened survival (30‑32). Our previous 
study demonstrated that Ehm2/1 overexpression upregulated 
E‑cadherin expression and decreased the migration of MCF‑7 
cells (14). The results of the present study also demonstrated 
that Ehm2/1 and Ehm2/2 regulated the migration and invasion 
of A549 cells, key hallmarks of EMT. These findings led us 
to hypothesize that Ehm2/1 and Ehm2/2 may also regulate 
EMT in A549 cells. In line with this hypothesis, we found 
that Ehm2/1 inhibited EMT, while Ehm2/2 promoted EMT. 
This finding is indeed noteworthy and is in accordance to 
an ongoing finding in breast cancer, where we demonstrated 
that Ehm2/1 may stabilize E‑cadherin by inhibiting its 
ubiquitination and degradation. These two studies were 
on different types of cancer and used different cell types, 
and suggest that Ehm2 is more widely involved in EMT in 
different cancer types and that different variants may have 
contrasting effects on EMT; these findings warrant further 
investigation in the future.
MMPs are a family of enzymes involved in the degradation 
of the extracellular matrix (ECM) and play important 
roles in tumor invasion and metastasis (33). High levels of 
MMP2 expression are often associated with metastasis (34). 
Studies have demonstrated that MMP2 leads to EMT via the 
proteolytic degradation of epithelial cell junctional proteins in 
carcinomas (35). MMP2 and MMP9, also known as gelatinases, 
play an important role for cleaving type I, IV collagen and 
contribute to the process of metastasis (36). In this study, in 
accordance with the data obtained from cell invasion assay, 
both the knockdown of Ehm2/1 and the overexpression of 
Ehm2/2 increased the activity of MMPs, including MMP2 and 
MMP9, suggesting that the regulation of MMPs in a different 
manner by different Ehm2 variants is another mechanism 
underlying their role in cancer metastasis. From this point of 
view, it is very important to compare the two Ehm2 variants 
in primary and matched metastatic cancers. Unfortunately, 
our collection was small and only had one metastatic cancer 
out of the 15 lung cancer tissues making it difficult to draw a 
clear conclusion. However, we are currently collecting a larger 
tissue cohort, and hopefully with a longer follow‑up of the 
patients, we would be in a position to conduct the comparison 
in near future.
In conclusion, the present study demonstrated that 
the Ehm2 variant, Ehm2/1, was downregulated in lung 
adenocarcinoma tissues and that these lower levels of 
Ehm2/1 were associated with a poorer survival. In vitro cell 
function assays indicated Ehm2/1 acted as an anti‑oncogene 
in lung adenocarcinoma cells. This study also demonstrated 
that the other variant, Ehm2/2, had a contrasting pattern 
of expression from that of Ehm2/1, namely that it was 
upregulated in lung adenocarcinoma cells and higher levels 
of Ehm2/2 were associated with a poorer clinical outcome 
of patients with lung cancer. Cell function assays indicated 
that Ehm2/2 acted as an oncogene in lung adenocarcinoma 
cells. Moreover, Ehm2/1 inhibited the invasion and migration 
of lung cancer cells via the regulation of EMT, while Ehm2/2 
increased the invasiveness and motility of lung cancer cells 
by promoting EMT. Our research provides new evidence 
that different transcript variants of a gene can play different, 
even opposing, roles. It will be necessary to validate these 
findings in in vivo models and accordingly we are currently 
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preparing recombinant lentivirus for overexpressing Ehm2/2 
and knocking down Ehm2/1 to order implement an orthotopic 
xenografts tumor model in BALB/c nude mice. Hopefully, 
these future investigation using in vivo models and indeed 
a larger clinical cohort would assist in answering some of 
questions relating to distant metastasis. Collectively, the 
current results from clinical samples and cellular experiments 
are sufficient to arrive at the conclusions that the two Ehm2 
variants have contrasting expression pattern in human lung 
adenocarcinoma and exert contrasting biological functions in 
lung cancer cells. The variants have important bearing to the 
disease progression of lung adenocarcinoma.
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